These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24122848)

  • 1. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.
    Hsu YC; Lin JT; Ho HJ; Kao YH; Huang YT; Hsiao NW; Wu MS; Liu YY; Wu CY
    Hepatology; 2014 Apr; 59(4):1293-302. PubMed ID: 24122848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection.
    Hsu YC; Ho HJ; Huang YT; Wang HH; Wu MS; Lin JT; Wu CY
    Gut; 2015 Mar; 64(3):495-503. PubMed ID: 25398770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
    Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.
    Hsu CS; Kao JH; Chao YC; Lin HH; Fan YC; Huang CJ; Tsai PS
    Aliment Pharmacol Ther; 2013 Aug; 38(4):415-23. PubMed ID: 23802888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
    Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
    Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden associated with patients diagnosed with hepatitis C.
    McCombs JS; Yuan Y; Shin J; Saab S
    Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
    Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
    Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
    Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
    Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.
    Lin SY; Chen TC; Lu PL; Lin CY; Lin WR; Yang YH; Chen YH
    BMC Infect Dis; 2014 Dec; 14():705. PubMed ID: 25523602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.
    Arase Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Hirakawa M; Ikeda K; Kumada H
    Hepatology; 2009 Mar; 49(3):739-44. PubMed ID: 19127513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
    Su TH; Liu CJ; Tseng TC; Chou SW; Liu CH; Yang HC; Wu SJ; Chen PJ; Chen DS; Chen CL; Kao JH
    Aliment Pharmacol Ther; 2019 Feb; 49(3):331-339. PubMed ID: 30592071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
    Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
    J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
    Lok AS; Everhart JE; Chung RT; Padmanabhan L; Greenson JK; Shiffman ML; Everson GT; Lindsay KL; Bonkovsky HL; Di Bisceglie AM; Lee WM; Morgan TR; Ghany MG; Morishima C;
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):245-54. PubMed ID: 17296533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
    Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
    Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.